Priveq Investment successfully concluded a profitable exit from Biovitrum, achieving over 26x returns and an IRR exceeding 80 percent, highlighting the potential of the Swedish pharmaceutical market.

Information on the Target

Priveq Investment has successfully closed an exit transaction that was initiated on November 5th, 2009. This exit marks a significant milestone as it is recognized as the most successful investment in terms of money multiple achieved over the firm’s 27-year history. The completion of this transaction was contingent upon a favorable outcome from the Biovitrum Extraordinary General Meeting (EGM) held on December 4th, 2009.

This strategic exit resulted in a remarkable investment return of over 26 times the original capital, with the potential for an additional 3 times return based on the future performance of the company. The internal rate of return (IRR) on this investment exceeded 80 percent, showcasing the exceptional financial performance of the investment over its lifecycle.

Industry Overview in Sweden

The pharmaceutical industry in Sweden is renowned for its innovative research and development capabilities, particularly within specialized fields. The country boasts a robust ecosystem of life sciences, underpinned by